Alpha Tau Medical Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Alpha Tau Medical Ltd., a foreign private issuer, for the month of December 2025. The report, dated December 4, 2025, serves to furnish a press release regarding upcoming scientific presentations rather than reporting financial results.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report of a corporate event and does not contain financial statements or key performance indicators.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document focuses solely on the announcement of clinical data presentations.
Outlook, Commentary, and Risks
Management announced that the Company will present two abstracts regarding its Alpha DaRT pancreatic cancer therapy at the upcoming 2026 ASCO GI Symposium. The filing includes standard legal disclaimers stating that the information is furnished and not "filed" under Section 18 of the Exchange Act, limiting liability and incorporation by reference.
Key Facts for Investor Verification
- The Company is presenting two abstracts on Alpha DaRT for pancreatic cancer at the 2026 ASCO GI Symposium.
- The press release is attached as Exhibit 99.1 to this Form 6-K.
- No financial data or updated guidance is included in this specific filing.
- The report was signed by Uzi Sofer, Chief Executive Officer, on December 4, 2025.